The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).
 
Chelsea K. Osterman
No Relationships to Disclose
 
Dilip Sankar Babu
No Relationships to Disclose
 
Daniel M. Geynisman
Consulting or Advisory Role - Exelixis; Novartis; Pfizer
Research Funding - Genentech (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
 
Bianca Lewis
No Relationships to Disclose
 
Robert A. Somer
No Relationships to Disclose
 
Arjun Vasant Balar
Honoraria - Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Matthew R. Zibelman
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - US Patent No: 15/226,474 filed on 7/1/15 (Inst)
 
Elizabeth A. Guancial
Honoraria - UroToday
Consulting or Advisory Role - Genentech/Roche; Taris BioMedical
Speakers' Bureau - Genentech/Roche
 
Gianna Antinori
No Relationships to Disclose
 
Vivek Narayan
No Relationships to Disclose
 
Thomas J. Guzzo
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
David J. Vaughn
Research Funding - Merck Sharp & Dohme; Roche/Genentech
 
Chunkit Fung
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - Astellas Pharma; Exelixis; Novartis
Research Funding - Astellas Pharma (Inst)
 
Ronac Mamtani
Consulting or Advisory Role - Genentech/Roche; Takeda